Li Zhang, Md

This study is testing if a targeted drug (osimertinib) works better alone or combined with two chemotherapy drugs for people with advanced non-small cell lung cancer who have two specific genetic changes (EGFR and TP53 mutations). It aims to see which approach better controls the…